Business
KALY Leads in CBD ‘Boom’ Market and Stands Ready For Follow on US Marijuana Legalization
KALY Leads in CBD ‘Boom’ Market and Stands Ready For Follow on US Marijuana Legalization.
About this update from North American Cannabis Holdings, Inc.
[{"type":"text","content":"\nDALLAS, July 11, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) management today highlighted the recent launch of Innovation Shares’ The Cannabis ETF (THCX).  At the same time the cannabis pure play ETF was launched, the US House of Representatives began discussing the Federal Legalization of Marijuana.  KALY management views KALY’s strategy as an optimal fit into the cannabis investment opportunity reflected by the THCX launch and Federal Legalization of Marijuana discussion.\n Matt Markiewicz, Innovation Shares' managing director in Investors Business Daily: \"With several regulatory catalysts on the horizon in the U.S. and abroad, the current cannabis environment presents an exciting opportunity for investors,\" Markiewicz said. \"One area which has witnessed explosive growth since the signing of last year's U.S. farm bill is the hemp-derived CBD industry.\" \"Several of the companies in the portfolio are actively participating in this CBD boom by cultivating hemp, providing extraction services or by using CBD for applications in the pharmaceutical, health and consumer wellness markets,\" he noted. KALY has announced $15 million in hemp derived CBD extraction contracts.  KALY is leveraging its US Patented cannabis extraction process to establish a leadership position in the booming CBD market.  At the same time KALY is prepared to leverage its US Patented cannabis extraction process within the inevitably legalized US recreational marijuana market. A CNBC article reporting on the US House of Representatives discussion on the Legalization of Marijuana Federally, commented that, “Eleven states have legalized adult recreational use and a majority of Americans support legalization.”  KALY Pharma Business and PURA and USMJ Partnerships KALY is primarily a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from a proprietary cannabinoid product platform in a broad range of disease areas. In the fourth quarter of last year, 2018, KALY acquired NCM Biotech (NCMB). In NCMB’s four years of operations, the company has established a leading position in the development of plant-derived cannabinoid therapeutics through a proven drug discovery and pa...